JP2025510368A5 - - Google Patents

Info

Publication number
JP2025510368A5
JP2025510368A5 JP2024557758A JP2024557758A JP2025510368A5 JP 2025510368 A5 JP2025510368 A5 JP 2025510368A5 JP 2024557758 A JP2024557758 A JP 2024557758A JP 2024557758 A JP2024557758 A JP 2024557758A JP 2025510368 A5 JP2025510368 A5 JP 2025510368A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
dmt
meo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057857 external-priority patent/WO2023186816A1/en
Publication of JP2025510368A publication Critical patent/JP2025510368A/ja
Publication of JP2025510368A5 publication Critical patent/JP2025510368A5/ja
Pending legal-status Critical Current

Links

JP2024557758A 2022-03-27 2023-03-27 不安の処置 Pending JP2025510368A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000086 2022-03-27
EP22000083 2022-03-27
EP22000083.0 2022-03-27
EP22000086.3 2022-03-27
EP23153995.8 2023-01-30
EP23153939.6 2023-01-30
EP23153995 2023-01-30
EP23153939 2023-01-30
PCT/EP2023/057857 WO2023186816A1 (en) 2022-03-27 2023-03-27 Treatment of anxiety

Publications (2)

Publication Number Publication Date
JP2025510368A JP2025510368A (ja) 2025-04-14
JP2025510368A5 true JP2025510368A5 (enExample) 2026-04-07

Family

ID=86007166

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための5-MeO-DMT
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的/情動的引きこもりまたは離隔の処置のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための5-メトキシ-n,n-ジメチルトリプタミン

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための5-MeO-DMT
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的/情動的引きこもりまたは離隔の処置のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための5-メトキシ-n,n-ジメチルトリプタミン

Country Status (9)

Country Link
US (9) US20250205199A1 (enExample)
EP (7) EP4499075A1 (enExample)
JP (6) JP2025510368A (enExample)
KR (6) KR20250005183A (enExample)
CN (2) CN119095595A (enExample)
AU (6) AU2023246679A1 (enExample)
CA (6) CA3255505A1 (enExample)
IL (6) IL315891A (enExample)
WO (9) WO2023186826A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
EP4277894A1 (en) 2021-01-15 2023-11-22 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
DE502006008441D1 (de) 2006-08-01 2011-01-13 Stobi Gmbh & Co Kg Ventilballon für Inhalatoren
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
DK3927338T3 (da) * 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
KR20220008824A (ko) * 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
US20230157981A1 (en) * 2020-04-20 2023-05-25 Lobe Sciences Ltd. Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder
IL297861A (en) * 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
BR112022025306A2 (pt) * 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
WO2023186834A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt

Similar Documents

Publication Publication Date Title
JP2025510369A5 (enExample)
JP2025512831A5 (enExample)
JP2025510916A5 (enExample)
JP2025510295A5 (enExample)
JP2025511081A5 (enExample)
JP2025510912A5 (enExample)
JP2025511084A5 (enExample)
JP2025510294A5 (enExample)
Nayak et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
JP2025510296A5 (enExample)
JP2025510913A5 (enExample)
JP2020532531A5 (enExample)
JP2022524008A5 (enExample)
JP2022514194A5 (enExample)
CN107823195A (zh) R‑氯胺酮在抑郁症急性期治疗中的应用
BR112020005856A2 (pt) uso de uma composição contendo benzoato para tratar encefalopatia da glicina
JP2017508737A5 (enExample)
JP2024531799A5 (enExample)
JP2023537369A5 (enExample)
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
EP3999051B1 (en) Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease
JP7034314B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
JP2025511072A5 (enExample)
CN116251091B (zh) 一种预防和/或治疗神经病理性疼痛或并发症的药物组合物
JP2025510915A5 (enExample)